Neurosense Therapeutics is trading 13.37% up at $6.91, amid a broader risk-on session lifting biotechnology stocks.
- Major U.S. indexes are higher as investors respond to stronger industry demand, improving funding conditions, and renewed M&A optimism.
- No new company-specific announcement was identified for September 17, 2026.
- The September 9 reverse-split announcement is prior context, not a fresh catalyst.